FDA

Core Summary The U.S. Food and Drug Administration has officially approved an innovative drug for pancreatic cancer treatment, considered the most important therapeutic breakthrough in this field in decades. Pancreatic cancer, known as the “king of cancers” due to its high mortality rate and limited treatment options, now offers new survival hope for tens of thousands of patients with this new drug approval. Event Details According to The Wall Street Journal, this FDA approval marks a major milestone in pancreatic cancer treatment. Pancreatic cancer is the third leading cause of cancer death in the United States, with a five-year survival rate of only about 12%, far lower than most other common cancers. For a long time, treatment options have been largely limited to chemotherapy and surgery, with most patients diagnosed at advanced stages. ...

The U.S. Food and Drug Administration has officially cleared a blood test for Alzheimer’s disease developed by Roche and Eli Lilly. The test can accurately identify biomarkers of Alzheimer’s through a simple blood sample, eliminating the need for expensive brain scans or invasive cerebrospinal fluid tests. This milestone approval will significantly lower the threshold for early diagnosis, enabling millions of high-risk individuals to receive timely intervention.

The US Food and Drug Administration has approved Moderna’s mRNA flu vaccine for commercial use, ending a years-long regulatory review and opening new applications for mRNA technology in infectious disease prevention.

Trump Announces Dismissal of FDA Commissioner Makary Summary: President Trump has announced the dismissal of FDA Commissioner Robert Makary, citing policy disagreements with the White House. According to Reuters, U.S. President Trump has announced the dismissal of Food and Drug Administration (FDA) Commissioner Robert Makary. Makary, a prominent surgeon and public health researcher formerly at Johns Hopkins University, was nominated to lead the FDA in 2025. During his tenure, he advanced several drug approval reforms. ...

The White House is preparing to replace FDA Commissioner Marty Makary as the agency faces internal turmoil and credibility challenges.

White House Prepares to Replace FDA Commissioner Makary Amid Agency Turmoil The White House is preparing to replace FDA Commissioner Marty Makary, according to The Washington Post. President Trump has signed off on the ouster, senior officials confirmed. Makary’s tenure has been marked by internal policy disputes and personnel turmoil at the agency. The leadership change signals a potential shift in the FDA’s regulatory direction. Source: The Washington Post, Google News ...

[Brief] Trump Plans to Fire FDA Commissioner Marty Makary The New York Times reports that Trump has approved the dismissal of FDA Commissioner Marty Makary. This personnel change could shift the direction of US Food and Drug Administration policy. Makary has played a key role in drug approval and public health policy since taking office. A senior official confirmed Trump has signed off on the decision. Source: NYT

FDA Vaccine Studies Censored by Trump Administration After Finding Benefits of Shots According to a report by Ars Technica, the Trump administration reportedly blocked the U.S. Food and Drug Administration (FDA) from publishing research findings that demonstrated the benefits of vaccines – a move that has sparked strong concerns in the public health community. What Happened The report alleges that FDA researchers completed multiple studies showing positive vaccine outcomes, but these findings were subject to government-level intervention and censorship before publication. ...

The FDA has withdrawn multiple studies that had found Covid and shingles vaccines to be safe, raising concerns in the public health community.

The FDA commissioner publicly defended the agency’s drug approval decisions, responding to criticism from pharmaceutical companies and some lawmakers, emphasizing that approval standards will not be lowered under political pressure.